| 19.375 0.575 (3.06%) | 08-11 12:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 26.57 |
1-year : | 31.03 |
| Resists | First : | 22.75 |
Second : | 26.57 |
| Pivot price | 18.86  |
|||
| Supports | First : | 18.52 |
Second : | 15.9 |
| MAs | MA(5) : | 18.55 |
MA(20) : | 19.13 |
| MA(100) : | 18.77 |
MA(250) : | 16.31 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.1 |
D(3) : | 19.6 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 23.62 | Low : | 7.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRE ] has closed below upper band by 35.4%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.21 - 19.28 | 19.28 - 19.37 |
| Low: | 17.8 - 17.87 | 17.87 - 17.96 |
| Close: | 18.65 - 18.78 | 18.78 - 18.93 |
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Tue, 11 Aug 2026
Prenetics Global (PRE) to Announce Quarterly Earnings on Tuesday - MarketBeat
Sun, 09 Aug 2026
Price to earnings forward of Prenetics Global Limited – NASDAQ:PRE - TradingView
Sat, 08 Aug 2026
Prenetics Global (PRE) Q1 2026 earnings summary - Quartr
Fri, 07 Aug 2026
Prenetics Global Limited (PRE) details $1B IM8 customer financing - Stock Titan
Fri, 07 Aug 2026
Prenetics to Stream Q2 Results on Stocktwits Aug. 18 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 15 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 12.6 (%) |
| Shares Short | 666 (K) |
| Shares Short P.Month | 605 (K) |
| EPS | -3.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.13 |
| Profit Margin | -42 % |
| Operating Margin | -24.7 % |
| Return on Assets (ttm) | -13.6 % |
| Return on Equity (ttm) | -40.8 % |
| Qtrly Rev. Growth | 107.6 % |
| Gross Profit (p.s.) | 4.31 |
| Sales Per Share | 7.78 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -5.35 |
| PEG Ratio | 0 |
| Price to Book value | 2.72 |
| Price to Sales | 2.49 |
| Price to Cash Flow | -9.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|